Description
Overview
Cyto-Cellect® Fc Fusion provides a fluorescent assay that allows the users to directly detect and select the single cells that produce the highest amounts of Fc fusion proteins during Cyto-Mine® experiments. Cyto-Cellect® Fc Fusion, in conjunction with Cyto-Mine®’s high-throughput features, enables users to screen a large number of single cells based on their Fc protein productivity, increasing the chances of finding rare, high-quality clones.
Each kit contains 5 vials, each with the detection probes required for a single experiment. The assay probes are manufactured without the use of animal- or human-derived materials. Designed for ease of use, our detection kit is workflow-ready and compatible with CHO cell culture medium, enabling you to start your experiments with minimal effort.
Speed: Complete screens in a single day, eliminate months of project time
Ultra-high-throughput analysis: Find rare high-performing clones by screening hundreds of thousands of single cells per run
Single-Cell sensitivity: Directly detect Fc fusion proteins produced by single cells.
>99% Monoclonality Assurance: Built-in image analysis algorithm provides proof of monoclonality for each selected cell
Ease of use: Intuitive user interface and onboard automation
Features
Designed and validated for high-sensitive detections.
Compatible with picodroplets.
The assay responses co-relate to protein concentrations.
Uses recombinant proteins as assay probes. The reagents are filtered and subjected to biosafety tests.
Pre-optimized formulation. No user optimization is required.
Benefits
Enables high-sensitivity detection on single cells in picodroplets.
High-throughput analysis.
Enhance cell line development efficiency by enabling the selection and cloning of single cells based on productivity.
Sterile and AOF (Animal Origin Free).
Ease of use.
Discover the Cyto-Cartridge®
The Cyto-Cartridge® is the core of the Cyto-Mine® platform, providing all the necessary microfluidics for implementing picodroplet workflows.
The disposable cartridge is designed to be easy-to-use, ensuring zero cross-contamination between runs and maintaining the integrity and quality of your cells for each experiment.
Cyto-Cartridges® are manufactured from fully biocompatible materials under our ISO 9001 quality management system, in a clean environment.
Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
Cambridge, UK, [10 December 2024]: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to accelerate cell line development for Fc fusion manufacturing.
Cyto-Cellect Fc fusion is a robust, single-cell bioassay that leverages a novel fluorescent detection method and enables high-throughput detection of Fc fusion protein production from single cells in picodroplets. This assay is optimized for detection of Fc fusion proteins, an important class of biologic therapeutics. The new assay provides a sensitive and specific approach to detect these proteins in a single-cell format, allowing for high-throughput screening and rapid identification of cells producing high levels of Fc fusion proteins.
The Cyto-Cellect Fc Fusion assay kit expands on Sphere Fluidics’ existing portfolio of Cyto-Cellect® assays, offering unique capabilities for researchers to streamline their workflows in cell line development. The assay is fully compatible with Sphere’s new Cyto-Mine® Chroma platform as well as the first generation Cyto-Mine instrument, allowing for seamless integration into existing workflows.
The Cyto-Mine® Chroma platform combines single-cell dispensing, sorting, imaging, and clone verification in one automated, bench-top system. Powered by Sphere Fluidics’ patented microfluidic picodroplet technology, the Cyto-Mine® Chroma platform enables the rapid screening of millions of cells with unparalleled throughput, accelerating research in areas such as antibody discovery, cell line development, and cell engineering. The platforms’ high-throughput capabilities, combined with the Cyto-Cellect® Fc Fusion assay, make it an ideal solution for researchers working on recombinant protein development and therapeutic applications.
Dale Levitzke, CEO, Sphere Fluidics, said: “We are strategically-focused on scaling operations globally, which is reinforced by the establishment of our first comprehensive direct sales and support channel in the US. We are recruiting high-performing, experienced sales professionals and implementing a proven process for driving the right behaviors as we scale globally. These developments are essential for ensuring we proactively respond to market demand, enhance the customer experience, drive innovation, and grow the company.”
Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
Cambridge, UK, [10 December 2024]: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to accelerate cell line development for Fc fusion manufacturing.
Cyto-Cellect Fc fusion is a robust, single-cell bioassay that leverages a novel fluorescent detection method and enables high-throughput detection of Fc fusion protein production from single cells in picodroplets. This assay is optimized for detection of Fc fusion proteins, an important class of biologic therapeutics. The new assay provides a sensitive and specific approach to detect these proteins in a single-cell format, allowing for high-throughput screening and rapid identification of cells producing high levels of Fc fusion proteins.
The Cyto-Cellect Fc Fusion assay kit expands on Sphere Fluidics’ existing portfolio of Cyto-Cellect® assays, offering unique capabilities for researchers to streamline their workflows in cell line development. The assay is fully compatible with Sphere’s new Cyto-Mine® Chroma platform as well as the first generation Cyto-Mine instrument, allowing for seamless integration into existing workflows.
The Cyto-Mine® Chroma platform combines single-cell dispensing, sorting, imaging, and clone verification in one automated, bench-top system. Powered by Sphere Fluidics’ patented microfluidic picodroplet technology, the Cyto-Mine® Chroma platform enables the rapid screening of millions of cells with unparalleled throughput, accelerating research in areas such as antibody discovery, cell line development, and cell engineering. The platforms’ high-throughput capabilities, combined with the Cyto-Cellect® Fc Fusion assay, make it an ideal solution for researchers working on recombinant protein development and therapeutic applications.
Dale Levitzke, CEO, Sphere Fluidics, said: “We are strategically-focused on scaling operations globally, which is reinforced by the establishment of our first comprehensive direct sales and support channel in the US. We are recruiting high-performing, experienced sales professionals and implementing a proven process for driving the right behaviors as we scale globally. These developments are essential for ensuring we proactively respond to market demand, enhance the customer experience, drive innovation, and grow the company.”
Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.
Cambridge, UK, [10 December 2024]: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to accelerate cell line development for Fc fusion manufacturing.
Cyto-Cellect Fc fusion is a robust, single-cell bioassay that leverages a novel fluorescent detection method and enables high-throughput detection of Fc fusion protein production from single cells in picodroplets. This assay is optimized for detection of Fc fusion proteins, an important class of biologic therapeutics. The new assay provides a sensitive and specific approach to detect these proteins in a single-cell format, allowing for high-throughput screening and rapid identification of cells producing high levels of Fc fusion proteins.
The Cyto-Cellect Fc Fusion assay kit expands on Sphere Fluidics’ existing portfolio of Cyto-Cellect® assays, offering unique capabilities for researchers to streamline their workflows in cell line development. The assay is fully compatible with Sphere’s new Cyto-Mine® Chroma platform as well as the first generation Cyto-Mine instrument, allowing for seamless integration into existing workflows.
The Cyto-Mine® Chroma platform combines single-cell dispensing, sorting, imaging, and clone verification in one automated, bench-top system. Powered by Sphere Fluidics’ patented microfluidic picodroplet technology, the Cyto-Mine® Chroma platform enables the rapid screening of millions of cells with unparalleled throughput, accelerating research in areas such as antibody discovery, cell line development, and cell engineering. The platforms’ high-throughput capabilities, combined with the Cyto-Cellect® Fc Fusion assay, make it an ideal solution for researchers working on recombinant protein development and therapeutic applications.
Dale Levitzke, CEO, Sphere Fluidics, said: “We are strategically-focused on scaling operations globally, which is reinforced by the establishment of our first comprehensive direct sales and support channel in the US. We are recruiting high-performing, experienced sales professionals and implementing a proven process for driving the right behaviors as we scale globally. These developments are essential for ensuring we proactively respond to market demand, enhance the customer experience, drive innovation, and grow the company.”
